Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time 2024-03-18 20:32
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma 2024-02-20 21:00
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site 2024-01-08 22:00
WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan 2023-11-09 08:00
WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth 2023-10-30 20:01
WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022 2023-07-31 18:02
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022 2023-04-24 18:03
WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index 2022-12-21 08:00
WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan 2022-11-30 08:00
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion 2022-10-26 19:06
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility 2022-09-26 20:00
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers 2022-09-09 20:00
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware 2022-08-17 01:47
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology 2022-08-12 09:09
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility 2022-07-07 08:00
WuXi AppTec Reports Record First-Quarter In 2022 2022-04-25 17:52
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies 2022-03-08 08:00
Statement by WuXi AppTec Regarding Recent Market Fluctuation 2021-12-16 08:00
WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan 2021-12-09 08:00
WuXi AppTec Receives AA ESG Rating from MSCI 2021-09-06 08:00
1 2